pronai.investorroom.com

ProNAi Therapeutics, Inc. Investors - News Releases

Targeted Cancer Therapies using DNAi. These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below. Jul 21, 2015. ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares. Jul 15, 2015. ProNAi Therapeutics Announces Pricing of Initial Public Offering. Jun 23, 2015. Jun 18, 2015. Jun 16, 2015.

http://pronai.investorroom.com/

OVERVIEW OF pronai.investorroom.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR PRONAI.INVESTORROOM.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

July

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 17 reviews

5 star

9

4 star

3

3 star

4

2 star

0

1 star

1

Hey there! Start your review of pronai.investorroom.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

6.1 seconds

CONTACTS AT PRONAI.INVESTORROOM.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

10

SSL

EXTERNAL LINKS

10

SITE IP

64.78.159.10

LOAD TIME

6.063 sec

SCORE

6.2

PAGE TITLE

ProNAi Therapeutics, Inc. Investors - News Releases | pronai.investorroom.com Reviews

<META> DESCRIPTION

Targeted Cancer Therapies using DNAi. These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below. Jul 21, 2015. ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares. Jul 15, 2015. ProNAi Therapeutics Announces Pricing of Initial Public Offering. Jun 23, 2015. Jun 18, 2015. Jun 16, 2015.

<META> KEYWORDS

1 news

2 careers

3 corporate

4 overview

5 leadership

6 directors

7 dnai platform

8 how dnai works

9 programs

10 completed studies

CONTENT

Page content here

KEYWORDS ON PAGE

news,careers,corporate,overview,leadership,directors,dnai platform,how dnai works,programs,completed studies,clinical trials,dnai pipeline,publications,investors,news releases,events and webcasts,presentations,financial reporting,quarterly results,faqs

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

ProNAi Therapeutics, Inc. Investors - News Releases | pronai.investorroom.com Reviews

https://pronai.investorroom.com

Targeted Cancer Therapies using DNAi. These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below. Jul 21, 2015. ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares. Jul 15, 2015. ProNAi Therapeutics Announces Pricing of Initial Public Offering. Jun 23, 2015. Jun 18, 2015. Jun 16, 2015.

INTERNAL PAGES

pronai.investorroom.com

1

ProNAi Appoints Dr. Barbara Klencke as Chief Development Officer - Jun 23, 2015

http://pronai.investorroom.com/2015-06-23-ProNAi-Appoints-Dr-Barbara-Klencke-as-Chief-Development-Officer

Targeted Cancer Therapies using DNAi. The DNA Damage Response (DDR) Network. ProNAi Appoints Dr. Barbara Klencke as Chief Development Officer. June 23, 2015. CNW/ - ProNAi Therapeutics Inc.,. A clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced that it has appointed Dr. Barbara Klencke. And prior to that was the Group Medical Director in Product Development, Oncology at Genentech, Inc., having joined the company ...

2

ProNAi Therapeutics Announces Pricing of Initial Public Offering - Jul 15, 2015

http://pronai.investorroom.com/2015-07-15-ProNAi-Therapeutics-Announces-Pricing-of-Initial-Public-Offering

Targeted Cancer Therapies using DNAi. The DNA Damage Response (DDR) Network. ProNAi Therapeutics Announces Pricing of Initial Public Offering. July 15, 2015. CNW/ - ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of $17.00. Or from BofA Merrill Lynch, Attention: Prospectus Depart...

3

ProNAi Therapeutics, Inc. Investors - PNT2258 targeting BCL2

http://pronai.investorroom.com/pnt2258-targeting-bcl2

Targeted Cancer Therapies using DNAi. The DNA Damage Response (DDR) Network. Our Initial Target Oncogene BCL2, a Key Regulator of Apoptosis. In cancer patients, higher levels of BCL2 expression are generally correlated with poor prognoses and resistance to chemotherapies. By promoting cancer cell survival, BCL2 overexpression contributes to tumor formation and growth, as well as the subsequent development of chemo-resistance as observed in a broad variety of tumors. LNP Delivery Technology. In PNT225...

4

ProNAi Strengthens Leadership Team; Opens Vancouver Corporate Headquarters - Jun 16, 2015

http://pronai.investorroom.com/2015-06-16-ProNAi-Strengthens-Leadership-Team-Opens-Vancouver-Corporate-Headquarters

Targeted Cancer Therapies using DNAi. The DNA Damage Response (DDR) Network. ProNAi Strengthens Leadership Team; Opens Vancouver Corporate Headquarters. June 16, 2015. CNW/ - ProNAi Therapeutics Inc.,. Located at 2150 - 885 West Georgia Street, Vancouver, British Columbia. Canada, V6C 3E8. The company continues to maintain research operations in Plymouth, Michigan. Joining the company are:. Sukhi Jagpal, CA, CBV, MBA, Chief Financial Officer. Vice President of Human Resources. A world-leading center in t...

5

ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Jan 7, 2015

http://pronai.investorroom.com/2015-01-07-ProNAi-Initiates-Phase-II-Trial-of-PNT2258-in-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma-DLBCL

Targeted Cancer Therapies using DNAi. The DNA Damage Response (DDR) Network. ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). First Patient Dosed in the "Wolverine" Phase II Trial Evaluating ProNAi's BCL2 Targeting DNAi. And PLYMOUTH, MI. Jan 7, 2015. CNW/ - ProNAi Therapeutics Inc.,. A private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi. President...

UPGRADE TO PREMIUM TO VIEW 5 MORE

TOTAL PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

pronai.com

Leadership | ProNAi

http://pronai.com/leadership

Targeted Cancer Therapies using DNAi. Nick Glover, PhD. President and Chief Executive Officer. Angie You, PhD. Chief Business and Strategy Officer and Head of Commercial. Dr Barbara Klencke, MD. Sukhi Jagpal, CA, CBV, MBA. Keith Anderson, PhD. Senior Vice President of Technical Operations. Senior Vice President of Clinical Operations. Senior Vice President of Human Resources. Christian Hassig, PhD. Senior Vice President of Research. Senior Vice President of Global Regulatory Affairs and Head of Quality.

pronai.com

Directors | ProNAi

http://pronai.com/directors

Targeted Cancer Therapies using DNAi. Donald Parfet, MBA. Jeffrey H. Cooper, MBA. Nick Glover, PhD. Tran Nguyen, MBA. Nicole Onetto, MD. James Topper, MD, PhD. August 12, 2016. ProNAi Therapeutics Reports Second Quarter 2016 Results. June 6, 2016. ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL. June 1, 2016. ProNAi Therapeutics Appoints Dr. Christian Hassig as Senior Vice President of Research. May 26, 2016. May 18, 2016. 885 West Georgia Street. Vancouver, BC V6C 3E8. ProNA...

pronai.com

CORPORATE | ProNAi

http://pronai.com/corporate

Targeted Cancer Therapies using DNAi. August 12, 2016. ProNAi Therapeutics Reports Second Quarter 2016 Results. June 6, 2016. ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL. June 1, 2016. ProNAi Therapeutics Appoints Dr. Christian Hassig as Senior Vice President of Research. May 26, 2016. ProNAi Licenses Cancer Drug Candidate Targeting CDC7 from Carna Biosciences. May 18, 2016. ProNAi to Report Wolverine Phase 2 Interim Results on June 6th at ASCO. 885 West Georgia Street.

pronai.com

Completed Studies | ProNAi

http://pronai.com/pnt2258-targeting-bcl2/completed-studies

Targeted Cancer Therapies using DNAi. We have conducted two clinical trials with single-agent PNT2258 to date: a Phase 1 safety trial in 22 patients with relapsed or refractory solid tumors and a Phase 2 trial in 13 patients with relapsed or refractory NHL. Phase 1 dose escalation clinical trial. For more information, please go to Clinicaltrials.gov. Phase 2 trial in relapsed or refractory NHL. For more information, please go to Clinicaltrials.gov. August 12, 2016. June 6, 2016. June 1, 2016. ProNAi Ther...

pronai.com

PUBLICATIONS | ProNAi

http://pronai.com/publications

Targeted Cancer Therapies using DNAi. Final Results of PNT2258-02: A Pilot Phase 2 Study of PNT2258 for Relapsed or Refractory Non-Hodgkin’s Lymphoma. A Phase 2 Study of PNT2258 in Patients with Relapsed or Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): An Initial Report from the Wolverine Study. A Phase 2 Study of PNT2258 in Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL): The Wolverine Study. August 12, 2016. June 6, 2016. June 1, 2016. May 26, 2016. ProNAi to ...

pronai.com

PNT2258 targeting BCL2 | ProNAi

http://pronai.com/pnt2258-targeting-bcl2

Targeted Cancer Therapies using DNAi. PNT2258 is a drug candidate based on a novel therapeutic approach known as DNA interference (DNAi ). The DNAi oligonucleotides contained within PNT2258 are designed to target and hybridize with a complementary strand of genomic DNA associated with the BCL2 oncogene. ProNAi was evaluated in two studies prior to the Wolverine and Brighton Phase 2 trials:. The Wolverine Phase 2 study. For more information, please go to Clinicaltrials.gov. August 12, 2016. June 6, 2016.

pronai.com

Careers | ProNAi

http://pronai.com/careers

Targeted Cancer Therapies using DNAi. Join our growing team! Director, Program Management. Principal Scientist, Oncology. San Diego, CA). Senior Medical Director, Clinical Science (MD. San Francisco, CA). To apply for any of these job openings, please submit your CV and cover letter in PDF format to hr@pronai.com. With the position title in the subject line of your email. August 12, 2016. ProNAi Therapeutics Reports Second Quarter 2016 Results. June 6, 2016. June 1, 2016. May 26, 2016. May 18, 2016.

pronai.com

PROGRAMS | ProNAi

http://pronai.com/programs

Targeted Cancer Therapies using DNAi. ProNAi is focused on building a broad and diverse pipeline of promising oncology assets against emerging targets on the leading edge of cancer biology. We are developing PNT141, a potent, selective and orally bioavailable small molecule inhibitor of Cdc7. This kinase is a key regulator of both DNA replication and DNA damage response, making it a compelling emerging target for the potential treatment of a broad range of tumor types. August 12, 2016. June 6, 2016.

UPGRADE TO PREMIUM TO VIEW 2 MORE

TOTAL LINKS TO THIS WEBSITE

10

OTHER SITES

pronah.de

Neuigkeiten - ProNah

Wir stellen uns vor. Wie werde ich Mitglied. Zertifikat "gesicherte Nachhaltigkeit" für ProNah e.V. 2015. Die Zertifizierungsstelle des Deutschen priv. Instituts für Nachhaltigkeit and Ökonomie bescheinigt dem Verein ProNah e.V. Nachhaltigkeit in den Bereichen Ökologie, Ökonomie und Sozialkompetenz. Erteilt wurde zudem das Prüfsiegel 2015 "gesicherte Nachhaltigkeit". Weiterlesen Zertifikat "gesicherte Nachhaltigkeit" für ProNah e.V. 2015. TVA Regionalmagazin "Aus dem Unterallgäu und Memmingen". Kaufe ich...

pronahi-reduform.com

PRONAHI-REDUFORM

REDUFORM empresa 100% mexicana, creadora del programa REDUFORM,. Te agradece tu visita y te invita a que conozcas su variedad de productos y programas pensados y elaborados para tu salud. Objetivo de la compañía . Brindar a nuestros clientes la mejor opción en productos naturales. Perfil de la compañía . Productos Naturales de Hidalgo nace como Microempresa en el mes de febrero del 2003 fabricando productos de origen natural para ayudar a. Resolver problemas de Salud Pública y de cuidado personal,. Eres ...

pronahiorganic.com

ZOGA IT Web Experts desarrollo de Sistemas basados en Web, paginas web, comercio electrónico, Intranets, Extranets, MAshups, hosting de alto desempeño

Este Sitio Web se encuentra en desarrollo. Si usted tiene dudas o problemas con su servicio, por favor contacte con el soporte Técnico de Zoga IT.Web.Experts. Sitio Web Administrado por:. HTML / CSS / Servidores / Streaming / CM / App / Iphone / Ipad / IOS / Mashups / Apache / SEO / SMO / Hosting / Housing / Mail Services / Ajax / MySQL / PHP / Java / Open Source / Linux / Mac OS X / Unix / RSS / SSL / Ecommerce / Javascript / Analytics / Adwords / CMS / Google / Facebook / Youtube / B2B / B2C / IAB .

pronai.com

ProNAi | Targeted Cancer Therapies using DNAi

Targeted Cancer Therapies using DNAi. We are a clinical-stage oncology company pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi. Technology platform. Our vision is to be the leader in developing and commercializing a portfolio of DNAi-based therapies to deliver extraordinary therapeutic outcomes that dramatically change patients’ lives. A Phase 2 trial for the treatment of third-line relapsed or refractory DLBCL, and by mid-2015, we plan to initiate Brighton. Neova...

pronai.es

Pronai

Cami dels Gruixers. Reus (Tarragona). Calle Industria. Polígono Camps d’en Ricart. Pallejà (Barcelona). C/ de Juan de la Cierva. Canovelles (Barcelona). 8211; Main Menu –. POLÍGONO CAMPS D'EN RICART. Calle Industria. Polígono Camps d’en Ricart. Construcción de 8 naves industriales en la parcela E3. Inicio de las obras en 2010. Ver todas las promociones. Polígono H-12. Mas Sunyer. Localización: Cami dels Gruixers. Reus (Tarragona) Venta de parcelas en el nuevo Polígono Industrial. 08014 Barcelona, Spain.

pronai.investorroom.com

ProNAi Therapeutics, Inc. Investors - News Releases

Targeted Cancer Therapies using DNAi. These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below. Jul 21, 2015. ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares. Jul 15, 2015. ProNAi Therapeutics Announces Pricing of Initial Public Offering. Jun 23, 2015. Jun 18, 2015. Jun 16, 2015.

pronaieva.hu

Prónai Éva honlapja

A honlap 2014 februárjában frissült utoljára. Egyéb személyes információk ». 1 oldal a 2-ből. Hasonló honlapötleteket a quackit.com oldalon találsz.

pronaija.com

Pronaija | connecting professionals and clients in a timely manner

Let the world know what you do. LET THE WORLD KNOW WHAT YOU DO. Be there when consumers search for businesses like yours in Nigeria. USE PRONAIJA TO SEARCH FOR THE CITY'S PLUMBER, MECHANIC, ELECTRICIAN, TAXI DRIVER, CARPENTER TO THE BEST HOSPITAL, HOTEL, SHOPPING MALL, CHURCHES, MOSQUE IN YOUR NEIGHBOURHOOD. We are dedicated to helping local bussinesses like yours grow. PRONAIJA SOLVING PROBLEM IN A CLICK. Save yourself the stress, find professionals and companies from the comfort of your home.

pronail-fangus.com

פרדיקט | מערכת ניהול לקוחות

pronail-shamballa.com

PRONAIL Shamballa｜土浦　プロネイルシャンバラ

３級ジェル初級対応コース受講時間４０時間無料補講２時間. ２級ジェル中級対応コース受講時間１２０時間無料補講１０時間. １級ジェル上級対応コース受講時間２４０時間無料補講２０時間. LINE で登録で、お得なクーポン配信中 pronail-shamballa で検索してください。今話題の AUTO NAIL 導入しました。 JNA認定講師在籍ネイルスクール生徒募集中詳細はこちら. 7月11日土 7月12日日. 営業時間 10時 18時最終受付.

pronail.co.il

פרונייל מרכז שיווק והדרכה PRONAIL

ג'ל לק - NFU.OH המהפכה כבר כאן , כל טכנאית ציפורניים מתחילה וותיקה מניקוריסטית ופדיקוריסטית יכולה להיות אמנית. מכונות שיוף ראשים מנורות Led. ראשים חכמים מנורות Led ועוד. גל אפקט konad gel effect. גל לק Gel Polish Konad. גל לק gel polish konad. ONE STEP GEL NFU.OH. One step gel nfu.oh. גלים לציור Gel Paint PRONAL. לקים Nfu.Oh Fs. לקים Nfu.Oh Vi. לקים Nfu.Oh CB. לקים Nfu.Oh Co. לקים Nfu.Oh Ho. פריימר, סילר, פרף ועוד. גל לק Nfu.Oh. גל לק 10ml Jbee. גל לק 14ml Frenz Nail. גל לק 17ml Gelist. הרמת חזה all up.